Since Humira has about 25% of the RA/autoimmune market, a $250M hit to Humira in 2015 from PFE’s JAK3 inhibitor is consistent with 2015 sales of about $1B for PFE’s drug. I don’t consider such a forecast out of line.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.